Kunzhong Zhou†
Yuewen Li†
Weifang Wang
Yilin Chen
Bingyan Qian
Yiteng Liang
Hongmei Li
Ruiting Xu
Li Zhuang*‡- Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China
A Correction on
SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance
By Zhou K, Li Y, Wang W, Chen Y, Qian B, Liang Y, Li H, Xu R and Zhuang L (2025) Front. Oncol. 15:1582738. doi: 10.3389/fonc.2025.1582738
Affiliation “Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China” was erroneously given as “Department of Rehabilitation and Palliative Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, China”.
In the published article, there was a mistake in the Funding statement. The Funding statement for the National Natural Science Foundation of China was displayed as “8226110412, 82460540”. The correct statement is “the National Natural Science Foundation of China (82260589, 82460540).’’
The funder the Multidisciplinary Talent Collaboration Platform for Tumor Support and Rehabilitation, 5222 to Li Zhuang was erroneously omitted.
The funder the Xishan District Talent Work Innovation Project: Construction of a Standardized Cancer Pain Diagnosis and Treatment Talent Collaboration Mechanism, 6015 to Li Zhuang was erroneously omitted.
The correct funding statement reads:
The author(s) declare that financial support was received for the research and/or publication of this article. This review was funded by the Translational Application Research Team Project of Precision Treatment and Diagnosis Strategies for Lung Cancer of Kunming Medical University (ZC2024XKTDPY08), the Special Project for Medical and Health Talents of the “Xingdian Talent Support Program” (CZ0096-901895), the National Natural Science Foundation of China (82260589, 82460540), the Multidisciplinary Talent Collaboration Platform for Tumor Support and Rehabilitation (5222), and the Xishan District Talent Work Innovation Project: Construction of a Standardized Cancer Pain Diagnosis and Treatment Talent Collaboration Mechanism (6015). The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.
The original version of this article has been updated.
Keywords: Schlafen11 (SLFN11), DNA damaging agents, PARP inhibitors, pan-cancer, DNA damage repair mechanisms, epigenetics, biomarkers
Citation: Zhou K, Li Y, Wang W, Chen Y, Qian B, Liang Y, Li H, Xu R and Zhuang L (2026) Correction: SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. Front. Oncol. 16:1779304. doi: 10.3389/fonc.2026.1779304
Received: 01 January 2026; Accepted: 21 January 2026; Revised: 20 January 2026;
Published: 04 February 2026.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2026 Zhou, Li, Wang, Chen, Qian, Liang, Li, Xu and Zhuang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Li Zhuang, emw3NzcxMjAxOTExMThAMTYzLmNvbQ==
†These authors share first authorship
‡ORCID: Li Zhuang, orcid.org/0000-0002-2487-463X